my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
TopoTarget is a dynamic international biotech company dedicated to finding "Answers for cancer". Founded by clinicians with a thorough knowledge of the molecular mechanisms of cancer, our goal is to find and develop cancer therapies, bringing them to the market to benefit patients. As well as a st more
TopoTarget is a dynamic international biotech company dedicated to finding "Answers for cancer". Founded by clinicians with a thorough knowledge of the molecular mechanisms of cancer, our goal is to find and develop cancer therapies, bringing them to the market to benefit patients. As well as a st more
TopoTarget is a dynamic international biotech company dedicated to finding "Answers for cancer". Founded by clinicians with a thorough knowledge of the molecular mechanisms of cancer, our goal is to find and develop cancer therapies, bringing them to the market to benefit patients. As well as a st more
SpePharm Holding, BV announced the acquisition of the worldwide (with the exception of North and South America) rights to Savene® from TopoTarget A/S. As part of the acquisition SpePharm will also take on the European sales force of TopoTarget. Savene®, which has been marketed by TopoTarget since it more
TopoTarget A/S announced that Francois Martelet, MD, takes up the position of CEO of TopoTarget in order to add the necessary late-stage clinical development and marketing expertise to ensure a successful development and commercialisation of belinostat, TopoTarget's lead anticancer drug. Dr. Franc more
Micromet, Inc. announced the appointment of Jan Fagerberg, M.D., Ph.D., as Senior Vice President and Chief Medical Officer effective November 1, 2009. Dr. Fagerberg is a board-certified clinical oncologist and has more than 20 years of experience in clinical research and development of oncology dr more
What will this decade hold for leading anti-cancer drugs and that therapeutic market? Our new report shows you anti-cancer drug revenue forecasts for 2011 to 2021. We provide research, data and opinions to benefit your work now. What revenues will cancer treatment markets generate from 2011 to 2021 more
TopoTarget A/S (TopoTarget) is a biotechnology company engaged in the discovery, development and commercialization of treatments for cancer patients, and other cancer-related disorders. The company also develops therapeutic for non-cancer diseases such as Acne, XLHED and Gout. Its product pipeline c more
27 June, 2007 - TopoTarget A/S (Copenhagen Stock Exchange: TOPO) announces the completion of the acquisition of Apoxis SA. Consistent with the growth strategy pursued by TopoTarget, the acquisition of the Swiss biotech company Apoxis SA will consolidate two emerging European oncology compani more
Language: en / da Sitemap Downloads Contact Search: Core Competences Pipeline Business Development Investor Join Us About Us Cancer Biodefence Infectious Diseases Investor News Media Clippings Share Information Financials Calendar General Meetings Presentations Investor Services Contact 30 March 20 more
Partnerships and Relationships Aeterna Zentaris Allergan, Inc. Altair Nanotechnologies, Inc. Bristol-Myers Squibb Company Indena SpA Johnson-Matthey Merck Eprova AG NDDO Oncology TopoTarget A/S Advanced Search | Home | Site Map | Contact Us | WebMail All contents © Copyright Spectrum P more
Watchlist
This is where you can add this topic to your personal favourites
Über CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2013 CHEMIE.DE Information Service GmbH, All rights reserved
Netmeeting
